Administration of recombinant interleukin·6 (IL·6) was found to induce in vivo generation of cytotoxic T lymphocytes (CTL) against syngeneic transplantable erythroleukemia (FBL·3) in lymph node cells and peritoneal exudate cells (PEC) in C57BL/6 mice. Furthermore, 15 out of 16 C57BL/ 6 mice injected with 5 X 10 6 viable FBL·3 cells survived on day 100 when they were treated with 5 X 10 4 U of recombinant IL·6 three times a day on days 1, 2, 3, 5, 7 and 9 after the inoculation of tumor cells (the cure rate was 94%). Cured mice could reject the tumor cells rapidly after the re·inoculation of a large number of live FBL·3 cells. In contrast, all normal mice died of tumor development by day 10. In these cured mice, FBL-3-specific CD4-S+ CTL cells were found to be generated in PEC, spleen anti-tumor effect. Administration of rIL·2 together with LAK cells was shown to exert anti-tumor effect against pulmonary and hepatic metastases of a variety of murine tumors. 12,13) Recently, murine tumors with the IL-2 or IL-4 gene were shown to be rejected by the activation of either CTL or non-specific anti-tumor activity in vivo. 14, IS) These results suggest the important roles of cytokines in the in vivo activation of anti-tumor effect.
The induction of CTL 4 in vitro requires the activation, proliferation and differentiation of CTL precursors and this process is regulated by several cytokines including IL-2.1~6) In vitro studies utilizing recombinant cytokines have revealed that IL-4, IL-5 and IL-6 function as KHF(s).7-1I) However, little is known about the role of these cytokines in the in vivo induction of CTL and anti-tumor effect. Administration of rIL·2 together with LAK cells was shown to exert anti-tumor effect against pulmonary and hepatic metastases of a variety of murine tumors. 12,13) Recently, murine tumors with the IL-2 or IL-4 gene were shown to be rejected by the activation of either CTL or non-specific anti-tumor activity in vivo. 14, IS) These results suggest the important roles of cytokines in the in vivo activation of anti-tumor effect.
IL-6 was originally identified as a B cell differentiation factor and its cDNA was cloned. '6 ) Subsequent studies have shown that IL-6 has a wide variety of biological functions as a myeloma growth factor, hepatocytestimulating factor, a multi-CSF and thrombopoietin. ' 7-2I) IL-6 acts not only on B cells but also on T cells as a T cell growth and differentiation factor. 7-9. 22-24) rIL-6 was demonstrated to function as a late-acting KHF in the 3 To whom correspondence should be addressed. .. Abbreviations used in this paper: CTL, cytotoxic T lymphocytes; IL-6, interleukin-6; r, recombinant; ML TC, mixed lymphocyte tumor culture; KHF, killer helper factor; FBL-3, a Friend virus-induced erythroleukemia; MMC, mitomycin-C; PEC, peritoneal exudate cells; Spl., spleen; LAK, lymphokine-activated killer; NK, natural killer; C', complement; mAb, monoclonal antibody. 1032 differentiation of human and murine CTL in vitro in our previous study.S) Therefore, in this study, we examined the effect of the in vivo administration of rIL-6 on the tumor rejection. The results demonstrate that IL-6 can augment the cure rate of mice bearing syngeneic FBL-3 tumor by the induction of the tumor-specific CTL in vivo.
MATERIALS AND METHODS
Reagents and antibodies Mitomycin C (MMC) was purchased from Kyowa Hakko Kogyo Co, Ltd. (Tokyo), concanavalin A (ConA) from Pharmacia Fine Chemicals (Uppsala), fetal calf serum (FCS, lot 508708) from Irvine Scientific (Santa Ana, CA). Anti-L3T4-, anti-Lyt 2.2 and anti-Thy 1.2 monoclonal antibodies were provided by Dr. K. Kuribayashi (Kyoto University, Kyoto), Dr. E. Nakayama (Nagasaki University, Nagasaki) and Dr. C. S. Henney (Immunex Co., Seattle, WA), respective1y.2~-27) Human rIL-6 (5 X 10 6 U/mg protein) was produced in Escherichia coli and purified as described. 28 ) The rIL-6 contained less than 0.3 ng of endotoxin/mg. 29 ) Human rIL-2 (5 X 10 7 U/mg protein) was a gift from Dr. J. Hamuro (Ajinomoto Co., Kawasaki).6) Tumor cell lines and mice FBL-3, a Friend virus-induced erythroleukemia (CS7BL/6 origin; H_2 . diluted) for 45 min at 37°C as described. B) Treatment of syngeneic tumor·bearing mice with rIL·6 and rIL·2 rIL-6 and rIL-2 were stabilized in 2% filter· sterilized normal C57BL/6 mouse serum and diluted to 5 X 10 4 VIO.75 ml and 5 X 10 3 VIO.75 ml in Hanks' balanced salt solution (HBSS), respectively. HBSS con· taining an equivalent concentration of normal mouse sera was used as control injections. C57BL/6 host mice (sixteen mice per each group) were inoculated ip with 5 X 10 6 FBL-3 cells on day 0, and were injected ip with either 5 X 10 4 V rIL-6, 5 X 10 3 V rIL-2, 5 X 10 4 V rIL·6 and 5 X 10 3 V rIL·2, or HBSS on days 1,2, 3, 5, 7 and 9 in three divided doses per day. In vitro induction of cytotoxic T cells from cured mice Mice cured of FBL·3 by administration of rIL-6 were killed on day 100. Then 3.5 X 10 6 spleen cells, mesenteric lymph node cells or PEC suspended in 2 ml of culture medium were cultured with 3.5 X 10' FBL-3 MMC in wells of a Linbro multi-well culture plate (No. 76-033-05).B) After 5 days, cells were harvested and used as effector cells in a cytotoxicity assay. The percent specific cytolytic activity was measured by means of a microcytotoxicity assay, using slCr-labeled FBL-3 as target cells. 3D) In vivo induction of cytotoxic T cells from cured mice Mice cured of FBL-3 by administration of rIL-6 were re-inoculated ip with 3 X 10 7 viable FBL-3 cells. At various time intervals after FBL-3 immunization (4 to 21 days), animals were killed and the spleen, PEC, and mesenteric lymph node populations were obtained. Single cell suspensions from these populations were prepared as described.
2 ) These cells were tested for lytic activity. In vivo induction of cytotoxic T cells against syngeneic tumor by administration of rIL·6 C57BL/6 mice were immunized ip with 1 X 10 8 MMC-treated syngeneic FBL-3 tumor cells, and were injected ip with 5 X 10 4 U of rIL· Anti-tumor Effect of IL-6 by CTL Induction in vivo 6, 5 X 10 3 V of rIL-2, or HBSS for 6 days. Ten days after immunization, mesenteric lymph nodes and PEC were harvested and tested for lytic activity against FBL-3. Statistics Experimental data on cure rate in mice treated with lymphokines were statistically evaluated using the Kaplan.Meier test. 31, 32) RESULTS Systemic administration of rIL-6 induces in vivo CfL generation To study the role of IL-6 in the in vivo induction of CTL, rIL-6 was administered ip after immunization with mitomycin-treated FBL-3 cells. C57BL/6 mice were injected ip with 1 X lOB FBL·3 MMC followed by the administration of 5 X 10 4 V of rIL·6, 5 X 10 3 V of rIL. 2 or both IL·6 and IL-2 for 6 days. Cytotoxic activities against FBL·3 cells in lymph node cells and PEC on day 10 were assessed. As shown in anti-tumor effect against FBL-3, C57BL/6 mice were injected ip with 5 X 106 viable FBL-3 cells on day 0 and were treated ip with 5 X 10 4 U of rIL-6 three times a day on days 1,2, 3, 5, ,. and 9. As shown in Fig. 2 , 94% of the mice (15 mice out of 16 mice) given rIL-6 were alive on day 100. The cure rate in mice injected with rIL-6 was significantly higher than that of 31 % in mice injected with HBSS containing an equivalent concentration of normal mouse sera (P<O.OOI). The cure rate in mice treated with rIL-2 alone was 56% (9 mice out of 15 mice). The result indicates that IL-6 mediates an in vivo (Exp. I) C57BL/6 mice cured of FBL-3 by administration of rIL-6 were killed on day 100. Spleen cells (3.5 X 10 6 ) from cured mice and normal C57BL/6 mice were cultured with various numbers of FBL-3 MMC cells for 5 days. Cytotoxic activity against FBL-3 celJs was assessed at effector-to-target ratios of 30: 1 and 6:1. (Exp. II) 3.5 X 10 6 spleen cells from cured mice were cultured with 3.5 X 10' FBL-3 MMC cells. After 5 days of culture, cells were harvested and these effector cells were treated with monoclonal anti-Thy1.2, anti-CD4 or anti-CD8 antibody together with complement as described in "Materials and Methods." After treatment, effector celJs were assessed for cytotoxic activity at an effector-to-target ratio of 25: 1.
T cells from mice cured by rIL·6 showed specific cytolytic activity against FBL-3 in vitro To determine whether specific immunity is operative in mice cured by the administration of IL·6, the spleen cells of these mice were cultured with FBL-3 MMC under MLTC as described by Greenberg et al. 13 ) When 3.5 X 10 6 spleen cells from cured mice were cultured with FBL-3MMC ranging from 10 X lOs to 0.35 X lOs. cells for 5 days, a significant cytotoxic activity against FBL-3 was generated (Table  I) Anti-tumor Effect of IL-6 by CTL Induction in vivo together with complement, cytolytic activity was significantly abrogated. However, the depletion of CD4 + cells rather augmented the cytotoxic activity (Table I ). The result suggests that CD4 -S + CTL played a role in the therapeutic efficacy of IL-6 against syngeneic FBL-3 tumor. Cured mice rejected a large number of tumor cells To study in detail the role of IL-6 and CTL in cured mice, cured mice were re-inoculated with 3 X 10 7 viable FBL-3 cells. As shown in Fig. 3A , the maximal cytotoxic activity was observed in spleen cells, lymph node cells and PEC in cured mice on day 7 after re-inoculation of FBL-3 cells. All normal C57BL/6 mice died of FBL-3 tumors by day 10, and little cytotoxicity was generated in these mice (Fig. 3B) . On the other hand, all the mice cured by the rIL-6 treatment rejected the same number of FBL-3 cells but not EL-4 tumor cells. Prolongation of survival time was not observed in these cured mice in comparison with normal C57BL/6 mice, when viable EL-4 tumor cells were inoculated (data not shown). These effector cells were found to be cytotoxic to FBL-3, but not Y AC-1 (LAK-sensitive), EL-4, PSI5, and C57BL/6 spleen Fig. 2 were re-inoculated ip with 3 X 10 7 viable FBL·3 cells on day 100 after initial tumor injection. At intervals (on days 4, 7, 13, and 21) after FBL-3 reo immunization, animals were killed and spleen (D), PEC (e ), and mesenteric lymph node (0) populations were harvested. (B) As a control, normal age-matched C57BL/6 mice were inoculated ip with 3 X 10' live FBL·3 cells, then killed on day 4 or 7 and the peripheral lymphoid populations were harvested. These populations were tested for lytic activity against ,ICr_ labeled FBL-3 cells at EIT ratios of 1000:1, 300:1, and 200:1, in spleens, lymph nodes, and PEC, respectively. Spl. EfT ratio EfT ratio and 100 U/ml of rIL-2) at various EIT ratios. C57BL/6 mice cured by the administration of rIL-6 as shown in Fig. 2 were re-inoculated ip with 3 X 10 7 viable FBL-3 cells on day 100. On day 7 after FBL-3 re-inoculation, the animals were killed and mesenteric lymph nodes and PEC populations were harvested. These effector cells were treated with monoclonal anti-Thy 1.2, anti-CD4 or anti-CDS antibody together with complement. After treatment, effector cells were assessed for cytotoxic activity against FBL-3 cells at an effector-totarget ratio of 25: 1.
blast cells even at high ratios of effector to target (Fig.  4) . The results demonstrate that effector cells do not belong to the category of NK or LAK cells. Treatment of lymph node cells and PEC with anti-CDS or anti-Thy1.2 mAb together with C' almost completely abrogated the cytolytic activity. On the other hand, the depletion of CD4 + cells had no effect on the cytotoxic activity (Table  II) . The results suggested that r1L-6 played a role in mediating an anti-tumor effect via the in vivo induction of CD4-S+ CTL.
DISCUSSION
The present study demonstrated that in vivo administration of r1L-6 augmented the cure rate of C57BL/6 mice inoculated with syngeneic FBL-3 tumor cells by the augmentation of the induction of tumor cell-specific CTL. Several lines of evidence supported this conclusion. (i) When spleen and lymph node cells from mice cured by r1L-6 were cultured with FBL-3 MMC in vitro, CD4 -S + CTL against FBL-3 were generated. No CTL were generated from spleen and lymph node cells in normal mice. (ii) Effector CTL (CD4-S+) but not LAK cells were generated in vivo from PEC, spleen and lymph node cells in cured mice by the re-inoculation of FBL-3 cells. On the other hand, the inoculation of the same number of FBL-3 cells failed to induce CTL in normal C57BL/6 . mice. (iii) r1L-6 was found to inhibit in vitro proliferation of some tumors.33) The proliferation of FBL-3 cells in vitro, however, was not inhibited by the addition of rIL-6 ranging from 0.1 V/ml to 1O~ Vlml, even in the presence of r1L-2 (data not shown). Moreover, no direct cytotoxic effect of rIL-6 could be demonstrated on FBL-3 cells in a ~ICr 4-h release assay. Interferon r and tumor necrosis factor were shown to increase the sensitivity of target tumor cells to cytotoxic cells. 3 4-36) In contrast, the sensitivity of FBL-3 target cells to cytotoxic cells was not increased by rIL-6 at concentrations ranging from 0.1 VI mt to 5X 10 4 D/ml for 4S h (data not shown). These results indicated that the anti-tumor effect of r1L-6 was not mediated by a direct cytotoxic and/or cytostatic effect on FBL-3 tumor cells.
Murine plasmacytomas and mammary adenocarcinomas transfected with murine IL-4 cDNA were found to generate inhibitory activity for in vivo tumor growth. 1~) The anti-tumor effect of IL-4, however, was suggested to be mediated by an inflammatory infiltrate composed of macrophages and eosinophils, in contrast with the antitumor effect of IL-6 via CTL induction in the present study. It has not been elucidated whether systemic administration of IL-4 could be an efficient means for the eradication of tumors or not. Transfection of poorly immunogenic colon tumors with the gene for murine IL-2 was also found to elicit an anti-tumor effect by the induction of tumor-specific CTL. 14) IL-2 provided effectively by the transfected tumor cells was suggested to generate the CTL against poorly immunogenic tumors. In contrast, tumor-associated antigens encoded by the viral gene in immunogenic FBL-3 tumor cells could be recognized by helper T cells and CTL were elicited. 37 ) Actually, the anti-leukemia effect of high-dose IL-2 (5 X 10 4 V/day) even without the administration of immunocompetent cells was shown in mice bearing FBL-3 tumor.ll) Depletion of host T cells, either CD4 + or CDS +, but not NK-l.l + cells, reduced the therapeutic efficacy of IL_2.38) In this study, it was not examined whether CD4 + T cells were required for an anti-tumor effect of IL-6.
Maximal in vitro generation of FBL-reactive CDS+ CTL and the in vivo therapeutic activity of this subset were shown to be dependent on CD4 + helper T cells. 38.39) The addition of r1L-6 to MLTC including unprimed C57BL/6 splenic CD4 -S + T cells and FBL-3 MMC induced the generation of CTL in vitro against FBL-3 cells (data not shown). Furthermore, r1L-6 even when administered one day after the inoculation of FBL-3 MMC cells induced the generation of tumor-specific CTL in vivo in the present study. These results suggest that IL-6 functions as a KHF in the differentiation of CTL in vivo as well as in vitro. 8 Three distinct factors (IL-4, IL-5 and IL-6) were shown to be involved in the generation of the in vitro CTL. 7 -11 ) Therefore, it will be of interest to investigate whether IL-4 or IL-5 can augment the in vivo CTL generation and the anti-tumor effect induced by rIL-6. An anti-tumor activity of IL-6 mediating reduction in the number of micrometastases from sarcomas and adenocarcinoma has been reported by Mule et al. 41 ) It will be of interest to examine whether the administration of rIL-6 can be efficient for the eradication of poorly immunogenic tumors by the induction of CTL as well as for the eradication of immunogenic tumors. An approach utilizing poorly immunogenic tumors transfected with the IL-6 gene may be useful for elucidating this problem.
